Theravance Biopharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Theravance Biopharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $4.52M | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $4.28M | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $3.51M | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $3.09M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $5.69M | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $19.08M | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $5.47M | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $18.41M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $3.89M | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $10.70M | Mar 1, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.89M | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | $19.99M | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | $26.20M | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | $15.39M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $18.75M | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | $16.87M | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | $14.26M | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | $14.50M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $17.57M | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | $15.69M | Mar 7, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.02M | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | $3.62M | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | $54.84M | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | ($13.58M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($15.53M) | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | ($12.70M) | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | ($16.53M) | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | ($11.66M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($8.51M) | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | ($8.95M) | Mar 7, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.01M | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | ($6.46M) | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | ($2.73M) | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | ($14.43M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($9.20M) | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | ($10.84M) | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | ($15.71M) | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | ($11.21M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($6.24M) | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | ($8.76M) | Mar 7, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $485.57M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $354.16M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $382.00M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $607.40M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $374.82M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $469.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $408.83M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $560.24M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $441.40M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $639.25M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.72M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $175.55M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $213.00M | Mar 7, 2025 |
| FY2024 | Dec 31, 2022 | $441.80M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | ($338.57M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | ($303.75M) | Mar 1, 2023 |
| FY2022 | Dec 31, 2019 | ($223.84M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | ($51.59M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $115.18M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $350.23M | Feb 27, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 7, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 7, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.81M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $37.80M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $39.55M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $298.17M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $89.96M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $81.47M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $58.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $378.02M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $88.98M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $344.71M | Feb 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $616.33M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $619.17M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $455.04M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $454.35M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $223.75M | Feb 28, 2019 |